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Background: Ivacaftor, a cystic ﬁbrosis transmembrane regulator (CFTR) potentiator, decreased sweat chloride concentrations and improved
clinical measures in cystic ﬁbrosis (CF) patients with the G551D mutation.
Results: Sweat chloride measurements at day 15 had an overall positive predictive value (PPV) of 86.3%, a negative predictive value (NPV) of
65.5%, sensitivity of 73.9%, and speciﬁcity of 80.9% for an FEV1 improvement of ≥5% from baseline at week 16. For ivacaftor patients the
median FEV1 improvement was 16.7%; for placebo patients 0.4%. For patients aged 6–11 years who received ivacaftor and who had a sweat
chloride decrease of ≥40 mmol/L from baseline at day 15, a median weight gain of 11.2% at week 16, compared to 6% for those with a smaller
decrease was observed.
Conclusions: Changes in sweat chloride concentration at day 15 following treatment with ivacaftor may have sufﬁcient predictive potential to
identify individuals that show improvement in pulmonary function and weight gain after 16 weeks of treatment.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: PPV; Clinical outcomes; Ivacaftor; FEV1; Weight1. Introduction
Cystic fibrosis (CF), an autosomal recessive hereditary
disorder, results from reduced chloride transport across the
epithelia due to mutations in the gene encoding the CF trans-
membrane regulator (CFTR) protein, a chloride ion channel
[1,2]. The loss of chloride transport results in a range of clinical
manifestations, including a high sweat chloride concentration,
pancreatic and intestinal disorders, and progressive lung disease,
leading to a shortened life expectancy [3]. CF lung disease is
characterized by poor mucociliary clearance, resulting in chronic
infection and inflammation, airway plugging and bronchiectasis
[4,5].⁎ Corresponding author at: Vertex Pharmaceuticals Incorporated, 130Waverly
Street, Cambridge, MA 02139-4242, USA. Tel.: +1 617 961 7551; fax: +1 617
341 6803.
E-mail address: verena_seliger@vrtx.com (V.I. Seliger).
1569-1993/$ -see front matter © 2013 European Cystic Fibrosis Society. Published
http://dx.doi.org/10.1016/j.jcf.2013.03.004Approximately 5% of the CF population carries a copy of
the G551D CFTR mutation [6] and most of these patients
carry the F508del CFTR mutation on the other allele [7,8]. The
G551D CFTR mutation is a gating defect that causes loss of
chloride transport across epithelial membranes by preventing
the CFTR channel from opening [7,9–11]. The loss of chloride
transport in patients with G551D mutations is reflected by
a high sweat chloride concentration (mean ~108 mmol/L [12]),
a high incidence (N90%) of pancreatic insufficiency [13,14],
early clinical manifestations, and a rapid decline in lung func-
tion as measured by forced expiratory volume in one second
(FEV1) [13].
CFTR potentiators enhance chloride transport by acting directly
on CFTR to increase the gating activity of the channel [8]. In
clinical studies in patients carrying theG551Dmutation [6,15–18]
administration of ivacaftor (VX-770, KALYDECO™; Vertex
Pharmaceuticals Incorporated, Cambridge, MA, USA) [19], the
only currently-approved CFTR potentiator, resulted in aby Elsevier B.V. All rights reserved.
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Ivacaftor also improved lung function as measured by FEV1
and nutritional status as measured by weight gain [6,15–18].
The current post-hoc analysis was designed to determine
whether a short-term (15 day) change in sweat chloride concen-
tration could be used to predict a long-term (16 week) improve-
ment in FEV1 or weight gain.
2. Methods
2.1. Source of data
Data were obtained from two double blind, multicenter
studies in CF patients with G551D mutations described
previously [6,15–18]. Study 1 involved a cohort of 161 CF
patients ≥12 years, and study 2 involved 52 patients, of age
6–11 years. Across the two studies, 109 CF patients received
ivacaftor 150 mg every 12 h and 104 received placebo.
Sweat chloride concentration was measured throughout each
study. This post-hoc analysis focused on the values obtained at
day 1 (baseline) and on day 15, the first post-treatment sweat
chloride measurement.
FEV1 and weight were measured throughout each study. This
post-hoc analysis focused on the data at screening, day −14, day
1 and at week 16 values. In the study in children 6–11 years of
age, data were not collected at day −14.
2.2. Study population
All CF patients included in the current analyses carried
the G551D mutation. The analysis for FEV1 compared the
two groups that received ivacaftor or placebo. The analysis of
weight gain considered age groups: age 6–11 years or age
12 years and older at enrollment.
2.3. Statistical analysis
Baseline values were calculated as the values determined
for sweat chloride, FEV1, and weight, as mean of all available
individual measurements before the first administration of
ivacaftor or placebo.
The raw change of sweat chloride concentration was deter-
mined by calculating: (day 15 measurement − baseline).
The value of FEV1 and weight percent change at week
16 was obtained as: ((week 16 measurement − baseline) /
baseline) ∙ 100.
Patients were excluded from the analysis, if the following
were not available: values for the sweat chloride concentration
or sweat chloride raw change in concentration at day 15, or
values of percent change in FEV1, or in weight at week 16.
The mean, median, and the standard deviation were calculated
for sweat chloride, FEV1, and weight.
Statistical comparisons between those receiving ivacaftor or
placebo were performed using two-sided t-tests with α = 0.05.
In analysis 1 an FEV1 improvement of ≥5% from baseline
at week 16 is clinically regarded as being indicative of
providing clinical benefit in lung function. In analysis 2, aweight gain of ≥10% from baseline at week 16 is clinically
regarded as being indicative of providing clinical benefit in
weight gain.
The positive predictive value (PPV) for both an improve-
ment in FEV1 of ≥5% and a weight gain of ≥10% at week 16
was calculated for the binned intervals (10 mmol/L) of sweat
chloride concentration at day 15 (first interval 130–121, last
interval 30–21) and the binned intervals (10 mmol/L) of sweat
chloride raw change in concentration at day 15 (first interval
0–9, last interval 50–59) with sweat chloride concentration as
predictor.
The results of the ‘binned interval calculation’ were used as a
threshold determination for the sweat chloride concentration and
for the sweat chloride raw change in concentration as a predictor
for the further calculation of the statistics, including PPV, nega-
tive predictive value (NPV), sensitivity, and specificity.
Pearson's correlation was calculated for sweat chloride, FEV1,
and weight.
Statistical analyses were performed using Base SAS 9.2
(SAS Institute Inc., Cary, North Carolina, USA).
3. Results
3.1. Short-term changes in sweat chloride concentration and
long-term improvement in FEV1
The relationship between raw and raw changes in sweat
chloride concentration on day 15 and relative changes in FEV1
at week 16 after the first dose of ivacaftor or placebo were
evaluated. A significant (p b 0.0001) decrease in both the mean
sweat chloride concentration and the mean raw change from
baseline in sweat chloride concentration at day 15 was observed
for the full cohort of patients across the two studies (Fig. 1A
and B). Significant increases in mean FEV1 (p = 0.0006) and in
the mean percent change from baseline (p b 0.0001) in FEV1
were observed at week 16 (Fig. 1C and D).
No statistical correlation was observed between change from
baseline in FEV1 at week 16 and sweat chloride concentration
(ivacaftor: correlation: −0.05, p = 0.63; placebo: correlation:
–0.006, p = 0.96; Fig. 2A), or reduction in sweat chloride
(ivacaftor: correlation: −0.06, p = 0.56; placebo: correlation:
−0.04, p = 0.74; Fig. 2B) at day 15. However, scatter plots
show two distinct groupings of patients.
3.2. Likelihood of a meaningful improvement in FEV1 at week
16 based on sweat chloride concentration measures at day 15
Since no statistically significant correlation was found
between FEV1 and sweat chloride measures, long-term pre-
diction of an improvement in FEV1 ≥ 5% from baseline based
on short-term change in sweat chloride was investigated using
an algorithm (Fig. 3). An improvement of ≥5% in FEV1 from
baseline at week 16 is clinically regarded as being indicative of
providing clinical benefit in lung function in CF patients. The
binned intervals of 10 mmol/L in sweat chloride concentration
and 10 mmol/L raw change in sweat chloride concentration
from baseline were used to calculate PPVs for an improvement
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Fig. 1. Values and changes in sweat chloride concentrations (day 15), FEV1 (week 16), and weight (week 16) for ivacaftor and placebo treated patients. A: mean
sweat chloride concentration (mmol/L) at day 15 with a p b 0.0001 for ivacaftor treated patients (n = 93; mean at baseline: 101.3 mmol/L) versus placebo treated
patients (n = 86; mean at baseline: 102.0 mmol/L). B: mean sweat chloride concentration (mmol/L) raw change from baseline at day 15 with a p b 0.0001 for
ivacaftor treated patients (n = 93; mean at baseline: 101.3 mmol/L) versus placebo treated patients (n = 86; mean at baseline: 102.0 mmol/L). C: mean FEV1 (L)
level at week 16 with a p = 0.0006 for ivacaftor treated patients (n = 93; mean at baseline: 2.1 L) versus placebo treated patients (n = 86; mean at baseline: 2.0 L). D:
mean FEV1 (L) percent change at week 16 with a p b 0.0001 for ivacaftor treated patients (n = 93) versus placebo treated patients (n = 86). E: mean weight level (kg)
at week 16 for patients who are 6 to 11 years old (n = 41) and patients who are 12 years and older (n = 138), separated into two subgroups. Subgroup 1: patients who
are 6 to 11 years old who receive ivacaftor (n = 21; mean at baseline: 30.7 kg) and patients who receive placebo (n = 20; mean at baseline: 30.7 kg) and subgroup 2:
patients who are 12 years and older who receive ivacaftor (n = 72; mean at baseline: 62.1 kg) and patients who receive placebo (n = 66; mean at baseline: 61.2 kg).
F: mean percent weight gain from baseline of the subgroups of patients with age 6 to 11 years and patients age 12 years and older at week 16 with a p b 0.0001 for
ivacaftor treated patients versus placebo treated patients who are 6 to 11 years old, and a p b 0.0001 for ivacaftor treated patients versus placebo treated patients of
age 12 years and older. The I bars show the standard deviation in A–F.
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concentration was 80 mmol/L, and the threshold for the
raw change in sweat chloride concentration was 20 mmol/L.These thresholds were used to calculate PPV (86.3%),
sensitivity (73.9%), NPV (65.5%), and specificity (80.9%) for
an improvement in FEV1 of ≥5% from baseline at week 16
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Fig. 2. Relationship between short-term (15-day) change in sweat chloride concentration and long-term (16-week) FEV1 percent changes and weight percent changes for
the individual patients. A shows a scatter plot of the individual patients who received ivacaftor (closed triangle) (n = 93) and who received placebo (open triangle) (n = 86).
The x-axis shows the sweat chloride concentration (mmol/L) at day 15 and the y-axis shows the FEV1 percent change from baseline at week 16. B shows a scatter plot of
the individual patients who received ivacaftor (closed triangle) (n = 93) and who received placebo (open triangle) (n = 86). The x-axis shows the absolute change in
sweat chloride concentration from baseline at day 15 and the y-axis shows the FEV1 percent change from baseline at week 16. C: scatter plot of the individual patients who
are 6 to 11 years old (n = 41) and who are 12 years and older (n = 138). The patients of age 6 to 11 years and the patients 12 years and older were additionally separated
into two subgroups: patients who received ivacaftor and patients who received placebo. The patients who are 6 to 11 years old and received ivacaftor are displayed as closed
triangles and those who received placebo are displayed as open triangles. The patients who are 12 years and older and received ivacaftor are displayed as closed diamonds
and those who received placebo as open diamonds. The x-axis shows the sweat chloride concentration (mmol/L) at day 15 and the y-axis shows the weight percent change
from baseline at week 16. D: scatter plot of the individual patients who are 6 to 11 years old and those who are 12 years and older. The x-axis shows the absolute change
in sweat chloride concentration from baseline at day 15 and the y-axis shows the weight percent change from baseline at week 16.
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group, to 88.0% and 98.8%, respectively, when a combi-
nation of both thresholds was taken into account in the
calculations (Table 1). The PPV was slightly higher for
children (6–11 years) (90.9%; 90.5% only ivacaftor) in
comparison with adults (≥12 years) (84.9%; 87.3% only
ivacaftor). The NPV and specificity for the placebo group,
calculated separately, were 66.3% and 96.5%, respectively
(Table 1). Among those who reached either of the sweat
chloride concentration threshold noted above, the median
improvement in FEV1 was 16.7% (n = 95; mean = 16.8%;
std = 13.5) versus 0.4% (n = 85; mean = 1.3%; std = 11.9) for
those who reached neither threshold.
3.3. Short-term changes in sweat chloride concentration and
long-term increase in weight
To investigate the relationship between raw values and raw
changes in sweat chloride concentration at day 15 and relativechanges in weight at week 16 after the first dose of ivacaftor or
placebo, groups were considered by age at initial enrollment:
6–11 years of age or ≥12 years. No significant difference
was seen between ivacaftor and placebo groups for mean
weight at week 16 in either age group (Fig. 1E). However, the
mean percent weight gain at week 16 was significantly higher
(p b 0.0001) among ivacaftor patients compared with placebo
patients in both age cohorts (Fig. 1F).
No statistically significant Pearson's correlation was found
for weight gain at week 16 and sweat chloride concentration
at day 15 in the 6–11 year old patients (ivacaftor: correlation:
−0.027, p = 0.91; placebo: correlation: −0.10, p = 0.66) or the
group of CF patients ≥12 years (ivacaftor: correlation: −0.09,
p = 0.45; placebo: correlation: 0.27, p = 0.03). Similarly, no
statistically significant Pearson's correlation was found for
patients 6–11 years of age for weight gain at 16 weeks and
the change from baseline in sweat chloride concentration at
day 15 (ivacaftor: correlation: −0.21, p = 0.36; placebo: −0.07,
p = 0.76) or for those ≥12 years (ivacaftor: correlation: –0.05,
Fig. 3. Algorithm for calculation of prediction of FEV1 improvement ≥5% from baseline at week 16 based on sweat chloride concentration at day 15 and sweat
chloride concentration absolute change from baseline at day 15.
710 V.I. Seliger et al. / Journal of Cystic Fibrosis 12 (2013) 706–713p = 0.70; placebo: correlation: 0.06, p = 0.62). However, scatter
plots show two distinct clusters for placebo and ivacaftor groups
for both comparisons (Fig. 2C and D).
3.4. Likelihood of a clinically meaningful weight gain at week
16 based on sweat chloride concentration measures at day 15
As no statistically significant correlation between percent
weight change from baseline and sweat chloride concentration
measures was found, an algorithm (Fig. 4) was used to calculate
the likelihood of weight gain at week 16 based on sweat
chloride concentration and on raw change in sweat chloride
concentration from baseline at day 15. Calculation of PPVs
for a weight gain≥10% from baseline at week 16 was based onTable 1
Positive and negative predictive value, sensitivity, and specificity for FEV1 ≥ 5% i
Sweat chloride threshold True
positive
(n)
True
positive
(%)
Pooled: ivacaftor and placebo, 179 patients
Decrease ≥ 20 mmol/L 82 45.8
Concentration ≤ 80 mmol/L 80 44.7
Decrease ≥ 20 mmol/L or concentration ≤ 80 mmol/L 82 45.8
Ivacaftor, 93 patients
Decrease ≥ 20 mmol/L 81 87.1
Concentration ≤ 80 mmol/L 79 85.0
Decrease ≥ 20 mmol/L or concentration ≤ 80 mmol/L 81 87.1
Placebo, 86 patients
Decrease ≥ 20 mmol/L 1 1.2
Concentration ≤ 80 mmol/L 1 1.2
Decrease ≥ 20 mmol/L or concentration ≤ 80 mmol/L 1 1.2the binned intervals of 10 mmol/L sweat chloride concentration
or 10 mmol/L raw change from baseline in sweat chloride
concentration and was performed separately for the cohorts
6–11 years of age and ≥12 years at enrollment. A threshold of
60 mmol/L in sweat chloride concentration, and a threshold of
40 mmol/L decrease in sweat chloride concentration at day 15
were found for patients 6–11 years. No threshold was found
for patients ≥12 years. For patients 6–11 years the median
percent weight gain was calculated for those patients who had a
sweat chloride decrease of 40 mmol/L or greater and for those
patients who had a sweat chloride decrease b40 mmol/L. All
patients who had a decrease of ≥40 mmol/L had received
ivacaftor. Their median percent weight gain from baseline was
11.2% (3.1 kg) at week 16. The patients who had a decreasen 179 patients who carry the G551D mutation on at least one allele.
Positive
predictive
value
Sensitivity True
negative
(n)
True
negative
(%)
Negative
predictive
value
Specificity
88.2 73.9 57 31.8 66.3 83.8
87.9 72.1 57 31.8 64.8 83.8
86.3 73.9 55 30.7 65.5 80.9
88.0 98.8 0 0.0 0.0 0.0
89.8 96.3 2 2.2 40.0 18.2
88.0 98.8 0 0.0 0.0 0.0
100.0 3.5 57 66.3 67.1 100.0
33.3 3.5 55 64.0 66.3 96.5
33.3 3.5 55 64.0 66.3 96.5
Fig. 4. Algorithm for calculation of prediction of median % weight gain from baseline at week 16. A weight gain of ≥10% from baseline at week 16 and sweat
chloride concentration at day 15 and absolute change in concentration from baseline at day 15 were used for the calculation of the positive predicted values (PPVs).
711V.I. Seliger et al. / Journal of Cystic Fibrosis 12 (2013) 706–713b40 mmol/L were separated into those patients, who had received
ivacaftor and those who had received placebo during the course
of the original study. The median percent weight gain for the
patients of age 6–11 years who received ivacaftor was 6.0%
(1.5 kg) and for the patients who received placebo 3.7% (1.2 kg).
Weight gain was also examined for patients using the
threshold of a sweat chloride concentration of 60 mmol/L. All
patients who had a sweat chloride concentration of≤60 mmol/L
had received ivacaftor. Their median percent weight gain from
baseline was 9.8% (2.8 kg). The patients who had a sweat
chloride concentration N60 mmol/L at day 15 were separated
into two groups, patients who received either ivacaftor or placebo
during the course of the original study. The median percent
weight gain for the patients of age 6 to 11 years who received
ivacaftor was 8.7% (2.0 kg) and for the patients who received
placebo 3.7% (1.2 kg).
4. Discussion
Cystic fibrosis is a ‘whole body' disease with many clinical
manifestations [20]. Markers are derived from several of these
disease manifestations to assess and predict the clinical course.
Each marker is individually valuable; however, attempts to
correlate the results obtained from different markers have been
only marginally successful, especially for those with differing
physiological bases [21]. In a recent publication [22] Durmowicz
et al. claim that there is no correlation for ivacaftor treated
patients between decrease in sweat chloride concentration and
improvement of FEV1, as has also been observed by the authors.
Dumrowicz et al. conclude that this devaluates sweat chloride
measurements as a marker for clinical endpoint determination.
This post-hoc analysis found that short-term changes in sweatchloride concentration show a high likelihood for longer-term
improvement in pulmonary function and weight gain.
In the post-hoc analysis no formal statistical correlation
between sweat chloride concentration measurements and FEV1
outcomes was observed. The progress of lung disease depends on
several factors. The primary factor, airway surface dehydration,
coexists with viral and bacterial infections leading to mucus
plugging, inflammation, and structural damage in the lung [4,5].
FEV1 reflects pulmonary function, affected by all adverse factors
present. In contrast, defective CFTR function appears to be the
only defect in the sweat gland, and no known structural damage
to the gland that impedes its function in CF patients.
The malfunction of the pancreas and intestinal systems in
patients is directly related to their inability to produce adequate or
functional CFTR. The low levels of CFTR function in CF patients
with the G551D mutation leads to pancreatic insufficiency in
the majority of these patients [13]. The intestines of these CF
patients are often affected by thick mucus and/or motility
problems resulting from inadequate epithelial chloride transport
[14,23]. Here again, many different factors influence inability to
digest food and absorb nutrients. As with FEV1, another clinical
measure affected by multiple physiological factors, weight gain
does not correlate with sweat chloride concentrations.
Although Pearson's correlations were not successful with
sweat chloride and these outcomes, it is still possible that sweat
chloride could be predictive of clinical improvements following
pharmaceutical interventions. Based on the characterization of
CF as a ‘whole body' disease we hypothesized, that any im-
provement in the function of CFTR channels that could be
measured by a decrease in sweat chloride concentration would
also be reflected by a status improvement of different organ
defects that are measured by FEV1 and weight gain.
712 V.I. Seliger et al. / Journal of Cystic Fibrosis 12 (2013) 706–713We analyzed the effect of ivacaftor, a new CFTR potentiator
drug for CF patients carrying the G551D mutation, because it is
the only therapeutic agent that has been shown to have clinically
meaningful effects on lung function and weight gain. In clinical
studies, ivacaftor treatment decreased sweat chloride concen-
tration, and was associated with improvements in lung function,
increased body weight and improvements in other clinical
symptoms of CF [6,15–18]. We demonstrated that decreases
in sweat chloride concentrations, improvements in FEV1 and
weight gain, are functionally linked during ivacaftor therapy.
Individual patient responses to therapy will differ even
within a population sharing the same genotype likely as a result
of various factors, such as age, progress of irreversible airway
destruction, infection status, and the influence of the genetic
or metabolic status. We examined individual responses in
scatter plots of individual correlations which showed a distinct
separation into two clusters, those who received ivacaftor and
those who received placebo. Individuals who received ivacaftor
and responded to this treatment by a rapid decrease of sweat
chloride concentration within two weeks, had a long-term im-
provement of their lung status as measured by FEV1 at 16 weeks.
This separation of clusters allowed the identification of
thresholds, of 80 mmol/L sweat chloride concentration or
20 mmol/L sweat chloride concentration decrease from base-
line at day 15. Notably, a sweat chloride concentration of
80 mmol/L is approximately 20 mmol/L lower than the mean
sweat chloride concentration at baseline in the populations
studied. These thresholds could be used for calculating the
improvement in FEV1 to be expected at 16 weeks. The relevance
of this prediction is indicated by the high PPV (86.3%) and
sensitivity of 73.9%, and specificity of 65.5% and NPV of 80.9%
for the total cohort of CF patients studied.
We also assessed whether an improvement in weight could
also be predicted for CF patients who received ivacaftor and had a
decrease in sweat chloride concentration within 15 days. Sweat
chloride had predictive value only in children age 6–11 years at
enrollment, who could be assumed to be growing. All children age
6–11 years who received ivacaftor had a significant increase in
weight relative to those who received placebo. For children who
received ivacaftor, a sweat chloride decrease of ≥40 mmol/L
at day 15 predicted a much more substantial increase in weight
relative to those who had a smaller decrease. Additionally, for the
children 6–11 years a threshold of 60 mmol/L of sweat chloride
concentration was found. However, there was no substantial
difference in weight gain between children who were above or
below this threshold and who received ivacaftor.
The present post-hoc analysis demonstrates a predictive
value for trends as opposed to the raw value at baseline of a
marker representing the status of a disease. The simple fact that
a certain short-term decrease of the patient's sweat chloride
concentration was achieved at 15 days of CFTR potentiator
treatment with ivacaftor, predisposed patients to long-term
improvements in pulmonary function as quantified by FEV1,
independent of medical history and health status when treatment
was initiated. A similar predictive value was identified for weight
gain in children 6–11 years suffering from CF, although no such
relationship was apparent in CF patients ≥12 years.These findings are of interest not only as diagnostic tools or
predictors of disease progression, but also in drug development.
The models we present open the possibility to design response-
based clinical studies using sweat chloride concentration as a
recruitment biomarker. Relevance to clinical decision making
is limited due to the relatively poor negative predictive value.
Therefore, while a fall in sweat chloride ≥20 mmol/L has good
positive predictive value, some ivacaftor responsive patients
may not demonstrate this sweat chloride decline. Therefore,
sweat chloride cannot be recommended as a tool to identify
ivacaftor non-responsive patients.
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